ClinicalTrials.gg
TerminatedNCT05099549Updated Mar 1, 2024

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

A Phase 1/2 interventional study of AFM24 and SNK01 in Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung and Colorectal Neoplasms, sponsored by NKGen Biotech, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by NKGen Biotech, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
834th of 993
11 · median 41
Started
2021
with 75 others
Phase 1/2
157 of 1,099
42 open now
Registered
791st of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 834th largest by enrollment of the 993 interventional ones that give a count, is one of 76 that started in 2021, is one of 157 in phase 1/2, and was the 791st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Read the detailed description

The study will be conducted in two phases. The Phase 1/dose escalation phase will gather preliminary safety and tolerability data for escalating doses of AFM24 in combination with SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to be used in the Phase 2a/expansion.

The Phase 2a/expansion portion of the study will gather additional safety, tolerability, efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in subjects with three types of advanced or metastatic EGFR-expressing cancers.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Advanced Solid Tumor
  • Refractory Tumor
  • Metastatic Tumor

Keywords

  • EGFR Positive
  • EGFR
  • EGFR+
  • AFM24
  • SNK01
  • Solid tumor
  • Lung cancer
  • Refractory
  • Metastatic
  • NSCLC
  • SCCHN
  • NK cells
  • Natural killer cell
  • IgG1
  • antibody
  • CD16A
  • ADCC
  • ADCP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Capable of giving signed
  2. Males and females age ≥ 18 years
  3. Phase 1/Dose Escalation : any confirmed advanced or EGFR-positive for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator.
  4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).
  5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below:

    1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received ≥ 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody.
    2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received ≥ 1 for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/ antibody.
    3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody.
  6. One or more measurable tumors lesions per v1.1
  7. (ECOG) performance status of 0 or 1
  8. Adequate bone marrow, hepatic and renal function.

Key Exclusion Criteria:

  1. Superior vena cava syndrome contra-indicating hydration
  2. Untreated or symptomatic central nervous system (CNS) metastases
  3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade ≤ 1 according to the v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia)
  4. Treatment with systemic anticancer therapy or an device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment.
  5. Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade > 1) toxicity from previous radiotherapy
  6. cardiovascular disease
  7. Major surgery within 4 weeks prior to any study treatment administration
  8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
  9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment.
  10. Known history of testing positive for (HIV), and/or positive test for virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.
  11. disease requiring therapy; immunodeficiency, or any disease process requiring systemic therapy
  12. A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
  13. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Phase 1, Dose Escalation

    It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants. SNK01 (fixed dose) will be administered weekly by IV infusion.

    Drug: AFM24 · Biological: SNK01

  • Experimental
    Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)

    SNK01 (fixed dose) will be administered weekly by IV infusion.

    Drug: AFM24 · Biological: SNK01

  • Experimental
    Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)

    SNK01 (fixed dose) will be administered weekly by IV infusion.

    Drug: AFM24 · Biological: SNK01

  • Experimental
    Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)

    SNK01 (fixed dose) will be administered weekly by IV infusion.

    Drug: AFM24 · Biological: SNK01

Interventions

  • DrugAFM24

    Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

  • BiologicalSNK01

    Patient-specific ex-vivo expanded autologous natural killer cells.

06

What researchers measure

Primary outcomes

  1. Phase 1/Dose Escalation

    Determine the maximum tolerated dose (MTD) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.

    Time frame: 28 days starting on cycle 1 day 1

  2. Phase 1/Dose Escalation

    Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.

    Time frame: 28 days starting on cycle 1 day 1

  3. Phase 2a/Expansion

    Determine objective response rate (ORR) of AFM24 in combination with SNK01. Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. Phase 1/Dose Escalation

    Assess safety and tolerability of AFM24 in combination with SNK01. Determine frequency and severity of treatment-emergent AEs (TEAEs) per National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI CTCAE v 5.0).

    Time frame: Up to 24 months

  2. Phase 1/Dose Escalation

    Determine preliminary efficacy of AFM24 in combination with SNK01. Determine ORR using RECIST v1.1 evaluated by local assessment.

    Time frame: Up to 24 months

  3. Phase 1/Dose Escalation

    Maximum observed plasma concentration (Cmax) of AFM24

    Time frame: 28 days starting on cycle 1 day 1

  4. Phase 1/Dose Escalation

    Time to maximum plasma concentration (Tmax) of AFM24

    Time frame: 28 days starting on cycle 1 day 1

  5. Phase 1/Dose Escalation

    Minimum plasma concentration (Cmin) of AFM24

    Time frame: 28 days starting on cycle 1 day 1

  6. Phase 1/Dose Escalation

    Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24

    Time frame: 28 days starting on cycle 1 day 1

  7. Phase 1/Dose Escalation

    Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 anti drug antibodies (ADAs) through completion of the Phase 1/dose escalation portion

    Time frame: Up to 24 months

  8. Phase 2a/Expansion

    Safety and tolerability of AFM24 in combination with SNK01 Frequency of TEAEs graded according to NCI CTCAE v 5.0

    Time frame: Up to 24 months

  9. Phase 2a/Expansion

    To assess progression-free survival (PFS) according to RECIST v1.1 by local assessment Assess the number of subjects with PFS defined as duration of time from start of combination treatment to date of progression.

    Time frame: Up to 24 months

  10. Phase 2a/Expansion

    To assess overall survival (OS).

    Time frame: Up to 24 months

  11. Phase 2a/Expansion

    To assess duration of response (DOR) according to RECIST v1.1 by local assessment.

    Time frame: Up to 24 months

  12. Phase 2a/Expansion

    To assess clinical benefit rate (CBR) according to RECIST v1.1 by local assessment.

    Time frame: Up to 24 months

  13. Phase 2a/Expansion

    Maximum observed plasma concentration (Cmax) of AFM24.

    Time frame: 28 days starting on cycle 1 day 1

  14. Phase 2a/Expansion

    Time to maximum plasma concentration (Tmax) of AFM24.

    Time frame: 28 days starting on cycle 1 day 1

  15. Phase 2a/Expansion

    Minimum plasma concentration (Cmin) of AFM24.

    Time frame: 28 days starting on cycle 1 day 1

  16. Phase 2a/Expansion

    Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24.

    Time frame: 28 days starting on cycle 1 day 1

  17. Phase 2a/Expansion

    Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 ADAs and frequency of subjects developing neutralizing ADAs.

    Time frame: Up to 24 months

07

Study locations

3 sites
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • University of Chicago
    Chicago, Illinois 60611, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Sep 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Oct 29, 2021
StartActual
Nov 3, 2021
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05099549
Lead sponsor
NKGen Biotech, Inc.
Collaborators
Affimed GmbH
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Nov 3, 2021
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Mar 1, 2024

Study contacts

Paul Chang, MPH
study director · NKGen Biotech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-EGFR/CD16A Bispecific Antibody AFM24 · Troculeucel

Start the discussion